Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

65.85USD
23 Feb 2017
Change (% chg)

$0.56 (+0.86%)
Prev Close
$65.29
Open
$65.52
Day's High
$66.11
Day's Low
$65.35
Volume
6,855,571
Avg. Vol
11,091,856
52-wk High
$66.11
52-wk Low
$49.63

Select another date:

BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases

* In first phase 3 trial, Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects

BRIEF-Merck to record $2.9 bln impairment charge related to uprifosbuvir program - SEC filing

* On Feb 17, determined that it will record intangible asset impairment charge related to research program for MK-3682, uprifosbuvir - SEC filing

Merck drug prevents serious infection after marrow transplant: study

An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with placebo in a late state study, the company said.

BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda

* Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and merck’s keytruda® (pembrolizumab)

Merck stopping late stage study as another Alzheimer's drug fails

Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails

Feb 14 Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

Merck to halt study of mild to moderate Alzheimer's drug

Feb 14 Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.

BRIEF-Merck announces Epoch study of Verubecestat

* Merck announces epoch study of verubecestat for the treatment of people with mild to moderate alzheimer's disease to stop for lack of efficacy

BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial

* Merck's doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial

BRIEF-Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing

* Capital World Investors reports 5.1 percent passive stake in Merck & Co Inc as on December 30, 2016 - SEC Filing Source text: [http://bit.ly/2kkIx8A] Further company coverage:

Select another date:

More From Around the Web